Gilead Sciences Inc
NASDAQ: GILD
$92.38
+$1.38 (+1.5%)
Closing Price on January 15, 2025
GILD Articles
Apple Inc. (NASDAQ: AAPL) pushes for a ban on eight Samsung phones. (Reuters) Best Buy Co. Inc. (NYSE: BBY) will allow former chairman Richard Schulze to review its books with an eye toward a buyout...
Published:
The short interest in biotech stocks is generally rising, judging by the short interest changes from August 15 settlement date versus the July 31 settlement date. We have tracked the key short...
Published:
The short interest data is out from the July 31 settlement date and, with a couple of notable exceptions, short sellers generally have retreated from their gambles on biotech firms. For the period...
Published:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Tuesday morning. Amgen Inc. (NASDAQ: AMGN) raised to Buy at Lazard. American Tower...
Published:
Last Updated:
Gilead Sciences Inc. (NASDAQ: GILD) is seeing shares surge today on news that Bristol-Myers Squibb Co. (NYSE: BMY) has run into some unforseen safety issues with a hep-C candidate called INX-189. ...
Published:
Last Updated:
The three major US stock indexes opened higher this morning following European Central Bank president Mario Draghi’s promise to “do whatever it takes to preserve the euro” (our coverage here)....
Published:
Last Updated:
GileadGilead Sciences, Inc. (NASDAQ: GILD) has a product chest that includes Atripla, Truvada, Viread, Complera/Eviplera, and Emtriva for the treatment of HIV infection in adults. While Gilead has...
Published:
Last Updated:
GlobeImmune, Inc. is the latest biotech to file for an initial public offering. Financial terms were not disclosed but the first filing is for up to $69 million in common stock. This one has...
Published:
Last Updated:
Biotech is a sector which is often mixed with a hodge-podge of winners and losers based on news flow from analysts and/or key drug developments which often have very little to do with the broad...
Published:
Last Updated:
News from Abbott Laboratories (NYSE: ABT) on its positive Phase II study results from two different interferon-free hepatitis C treatment has the entire drug sector up in arms as it pertains to...
Published:
Last Updated:
Jon OggEach weekend we review the many analyst calls we track during the week. Some turn out to be very insightful and some turn out to be not so great. For better or worse, these become the top...
Published:
Last Updated:
US equities markets opened lower this morning following surprisingly weak manufacturing reports from Europe and China. Fitch Ratings’ downgrade of Greek debt to ‘CCC’ could not have been a...
Published:
Last Updated:
Jon OggThese are some of this Wednesday’s top analyst upgrades, downgrades, and initiations seen in Wall Street research calls. Advanced Semiconductor Engineering, Inc. (NYSE: ASX) Cut to Neutral...
Published:
Last Updated:
US markets opened higher this morning and traded higher for most of the day. The DJIA briefly rose above 13,000 for the first time in nearly 3 years. But in the early afternoon, apparently as a...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Tuesday morning: ABB Limited (NYSE: ABB) Cut to Equal Weight at Morgan...
Published:
Last Updated:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.